NEW YORK (GenomeWeb) – Pacific Edge recently announced a contract with preferred provider organization MultiPlan covering Pacific Edge's Cxbladder test.
The deal provides coverage of the bladder cancer test to MultiPlan's members and includes Pacific Edge's participation in the MultiPlan, PHCS, and PHCS Savility Networks. About 900,000 providers participate in MultiPlan's networks and about 68 million patients have access to the networks, Pacific Edge said.
The Cxbladder test is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression. The test is run out of the company's wholly owned subsidiary Pacific Edge Diagnostics' CAP-accredited laboratory in Hershey, Pa.
Earlier this year, Pacific Edge received NZ$4.5 million (US$3.8 million) from New Zealand crown entity Callaghan Innovation to accelerate the firm's development of molecular cancer detection technology.